HCV New Drug Research: Hepatitis-C and its Effects on Liver Transplantation

Hepatitis-C and its Effects on Liver Transplantation

Monday, June 27, 2011
Posted by New HCV Drugs
File Under transplant, video

Dr. K. Rajender Reddy, the Medical Director of liver transplantation at the Penn Transplant Institute, discusses the viral epidemic of hepatitis-c and its effects on liver transplantation.

Learn more about liver transplantation at the Penn Transplant Institute: http://www.pennmedicine.org/transplant/patient/liver/

View Dr. K. Rajender Reddy's profile: http://www.pennmedicine.org/wagform/mainpage.aspx?config=provider&p=pp&am...

Dr. Reddy was interviewed by Andrew Schorr, host and founder of Patient Power, at the 2011 American Transplant Congress.

Category:

Science & Technology

0 comments:

Post a Comment

In the US Vertex will be calling Telaprevir "INCIVEK" in Europe it will be called "Incivo" and Mercks Boceprevir is registered as "VICTRELIS"

Both of the new medicines work by blocking a protein called protease that the virus needs to replicate

How Do I Take Incivek-telaprevir ?
Included in the information will be the dosing regimen for Incivek in combination with pegIFN/RBV, and a list of drugs that could cause drug interactions if used while taking the combo.

Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.

HCV Genotypes and new possible therapies
Investigational drugs in the treatment of genotype 4
Hepatitis C virus resistance to protease inhibitors
Patient video; New hepatitis C Drugs and Resistance
Hepatitis C: current management and emerging therapies

New Drug Pipeline
New drugs in development for the treatment of hepatitis C

Telaprevir FDA Approved
Oct 11
INCIVEK(TM) (telaprevir) Now Available in Canada
Sept 20
European approval for hepatitis C drug, Telaprevir-Incivek "called Incivo in Europe."
Health Canada Okays INCIVEK For People With Hepatitis C
FDA Approves Telaprevir/Incivek For Hepatitis C

Boceprevir FDA Approved
Nov 22
Ontario first province to reimburse new chronic hepatitis C treatment VICTRELIS™ Now Available for Eligible Patients in Ontario
The Canadian Liver Foundation is pleased that Ontario’s public drug program has agreed to reimburse boceprevir for the treatment of chronic hepatitis C,” says Dr. Morris Sherman, Chairman of the Canadian Liver Foundation. “Boceprevir represents a major advance in our ability to cure this disease, and as a result, fewer patients will have to struggle with the consequences of end-stage liver disease, liver transplants and liver cancer. We applaud the research efforts that led to this breakthrough and hope other provinces will follow Ontario’s lead and rapidly reimburse this important treatment.”

Health Canada Clears Victrelis-Boceprevir New Hepatitis C Drug
MSD launches hepatitis C drug Victrelis in UK
Vicrelis/Boceprevir IS NOW FDA Approved May 13 2011

Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs

Of Interest
Use of New HCV Protease Inhibitors ‘Not That Simple’
Incivek/Victrelis; New approvals may change treatment for hepatitis C
FYI-Which New Hepatitis C Drug do MDs Prefer? Incivek vs. Victrelis
New Treatments For Hepatitis C; Boceprevir vs Telaprevir: What We Know and Don't Know
Getting Ready; Telaprevir or Boceprevir?
Boceprevir-victrelis-Which pegylated interferon?

Worth Reading
FDA Transcripts Telaprevir/Boceprevir April Advisory Committee Meeting Includes Side Effects

Medication Guides;
Telaprevir/Incivek Prescribing Information
Medication Guide
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Peginterferon alfa
Ribavirin

Blog
AASLD
The American Association for the Study of Liver Diseases November 2011 Annual Meeting

AASLD-Liver Learning
If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.

Web Site
AASLD Coverage Available On The Web Site
This AASLD Summary attempts to present recent data in an accessible format providing a greater understanding of current and future gentler HCV therapies that could be available in the near future.

Included are many of the investigational second-generation protease inhibitors and Interferon-free treatment regimens presented at this months meeting.

GET TESTED

Click here to order a FREE Home Access Hepatitis C Test Kit

How Soon Should I Get Tested After Exposure ?

After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;

FAIR USE NOTICE:

If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice

HCV New Drug Research

Hepatitis-C and its Effects on Liver Transplantation

Category:

0 comments:

Post a Comment

Data And Statistics